Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1986 1
1990 1
1992 1
1995 1
1999 3
2000 1
2001 1
2004 1
2008 1
2009 1
2011 2
2012 4
2013 3
2014 2
2015 1
2016 5
2018 1
2020 2
2021 2
2022 1
2023 1
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

36 results

Results by year

Filters applied: . Clear all
Page 1
p38MAPKα Stromal Reprogramming Sensitizes Metastatic Breast Cancer to Immunotherapy.
Faget DV, Luo X, Inkman MJ, Ren Q, Su X, Ding K, Waters MR, Raut GK, Pandey G, Dodhiawala PB, Ramalho-Oliveira R, Ye J, Cole T, Murali B, Zheleznyak A, Shokeen M, Weiss KR, Monahan JB, DeSelm CJ, Lee AV, Oesterreich S, Weilbaecher KN, Zhang J, DeNardo DG, Stewart SA. Faget DV, et al. Among authors: zheleznyak a. Cancer Discov. 2023 Jun 2;13(6):1454-1477. doi: 10.1158/2159-8290.CD-22-0907. Cancer Discov. 2023. PMID: 36883955 Free PMC article.
Role of CD47 as a marker of self on red blood cells.
Oldenborg PA, Zheleznyak A, Fang YF, Lagenaur CF, Gresham HD, Lindberg FP. Oldenborg PA, et al. Among authors: zheleznyak a. Science. 2000 Jun 16;288(5473):2051-4. doi: 10.1126/science.288.5473.2051. Science. 2000. PMID: 10856220
Nanotherapeutics for multiple myeloma.
Zheleznyak A, Shokeen M, Achilefu S. Zheleznyak A, et al. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2018 Nov;10(6):e1526. doi: 10.1002/wnan.1526. Epub 2018 Apr 26. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2018. PMID: 29701006 Free PMC article. Review.
Development of [89Zr]DFO-elotuzumab for immunoPET imaging of CS1 in multiple myeloma.
Ghai A, Zheleznyak A, Mixdorf M, O'Neal J, Ritchey J, Rettig M, DiPersio J, Shokeen M, Achilefu S. Ghai A, et al. Among authors: zheleznyak a. Eur J Nucl Med Mol Imaging. 2021 May;48(5):1302-1311. doi: 10.1007/s00259-020-05097-y. Epub 2020 Nov 11. Eur J Nucl Med Mol Imaging. 2021. PMID: 33179150 Free PMC article.
Imaging of hypoxia in mouse atherosclerotic plaques with (64)Cu-ATSM.
Nie X, Randolph GJ, Elvington A, Bandara N, Zheleznyak A, Gropler RJ, Woodard PK, Lapi SE. Nie X, et al. Among authors: zheleznyak a. Nucl Med Biol. 2016 Sep;43(9):534-542. doi: 10.1016/j.nucmedbio.2016.05.011. Epub 2016 May 30. Nucl Med Biol. 2016. PMID: 27372286 Free PMC article.
Evaluation of (89)Zr-pertuzumab in Breast cancer xenografts.
Marquez BV, Ikotun OF, Zheleznyak A, Wright B, Hari-Raj A, Pierce RA, Lapi SE. Marquez BV, et al. Among authors: zheleznyak a. Mol Pharm. 2014 Nov 3;11(11):3988-95. doi: 10.1021/mp500323d. Epub 2014 Aug 5. Mol Pharm. 2014. PMID: 25058168 Free PMC article.
Development of New CD38 Targeted Peptides for Cancer Imaging.
Zheleznyak A, Tang R, Duncan K, Manion B, Liang K, Xu B, Vanover A, Ghai A, Prior J, Lees S, Achilefu S, Kelly K, Shokeen M. Zheleznyak A, et al. Mol Imaging Biol. 2024 Mar 13. doi: 10.1007/s11307-024-01901-5. Online ahead of print. Mol Imaging Biol. 2024. PMID: 38480650
36 results